Mein Warenkorb

IL-4 R alpha

IL-4 R alpha Molekülinformation

Englischer NameInterleukin-4 receptor subunit alphaAnzahl der inverkehr gebrachten Arzneimittel2
Anzahl der klinischen Arzneimittel24Target-AliasInterleukin 4 Receptor,IL-4 Receptor Subunit Alpha,Interleukin 13 Receptor,IL4RA,Interleukin-4 Receptor Subunit Alpha,Interleukin-4 Receptor Alpha Chain,IL4R Nirs Variant 1,IL-4R Subunit Alpha,CD124 Antigen,Interleukin-4 Receptor alpha Subunit,IL4Rα,IL-4R-alpha,Soluble IL-4 receptor subunit alpha,582J2.1,Soluble IL-4R-alpha,IL-4-binding protein,IL-4RA,IL4-BP,sIL4Ralpha/prot,CD124,IL4R
Höchste Forschungs- und EntwicklungsphaseApproved
Englischer NameInterleukin-4 receptor subunit alpha
Target-AliasInterleukin 4 Receptor,IL-4 Receptor Subunit Alpha,Interleukin 13 Receptor,IL4RA,Interleukin-4 Receptor Subunit Alpha,Interleukin-4 Receptor Alpha Chain,IL4R Nirs Variant 1,IL-4R Subunit Alpha,CD124 Antigen,Interleukin-4 Receptor alpha Subunit,IL4Rα,IL-4R-alpha,Soluble IL-4 receptor subunit alpha,582J2.1,Soluble IL-4R-alpha,IL-4-binding protein,IL-4RA,IL4-BP,sIL4Ralpha/prot,CD124,IL4R
Anzahl der inverkehr gebrachten Arzneimittel2
Anzahl der klinischen Arzneimittel24
Höchste Forschungs- und EntwicklungsphaseApproved

IL-4 R alpha Molekülhintergrund

IL-4 is a pleiotropic cytokine produced by activated Th2 cells and mast cells, and plays a pivotal role in immune responses. The effects of IL-4 are mediated after binding to high affinity receptor complexes present on hematopoietic as well as non-hematopoietic cells. Hematopoietic cellular responses to IL-4 are mediated by a high affinity receptor complex comprised of the 140 kDa IL4Rα (CD124)subunit and the 70 kDa common cytokine γc chain (CD132). Interleukin 4 Receptor (IL4R) also known as CD124, IL4Rα and BSF receptor, is a type I cytokine receptor produced by activated Th2 cells and mast cells, and plays an important role in Th2-­biased immune responses, alternative macrophage activation, mucosal immunity, allergic inflammation, tumor progression, and atherogenesis. A soluble form of the encoded IL4R protein can be produced by an alternate splice variant or by proteolysis of the membrane-bound protein, and this soluble form can inhibit IL4-mediated cell proliferation and IL5 upregulation by T-cells. IL4R can alternatively associate with IL­13Ra1 to form the type II receptor which is responsive to both IL­4 and IL­13. Interleukin-4 receptor has been shown to interact with SHC1.

IL-4 R alpha Molekülalias

IL4R,CD124,IL4RA

Klinische Arzneimittelinformation

Englischer NameForschungscodeForschungsphaseFirmaIndikationenKlinische Studie
OturkibartHDM3016; QX-005N; HDM-3016Phase 3 ClinicalQyuns Therapeutics Co LtdAsthma; Chronic Urticaria; Dermatitis, Atopic; Nasal Polyps; Prurigo; Pulmonary Disease, Chronic Obstructive; Sinusitis
Details
Dupilumab biosimilar (Jingxing Pharmaceutical)GS101; GS-101; GS-101 (Jingxing Pharmaceutical)Phase 3 ClinicalJiangsu Jingxing Pharmaceutical Technology Co LtdDermatitis, Atopic
Details
Dupilumab biosimilar (Qilu Pharma)QL2108; QL-2108Phase 3 ClinicalQilu Pharmaceutical Co LtdAsthma; Dermatitis, Atopic; Prurigo
Details
siLR4AsiLR4APhase 3 ClinicalNational Skin Centre, SingaporeKeloid; Wounds and Injuries
Details
TQH2722TQC2722; TQC-2722; TQH 2722; TQH-2722; TQH2722; BSI-045APhase 3 ClinicalBiosion Inc, Nanjing Shunxin Pharmaceuticals Co Ltd Of Chiatai Tianqing Pharmaceutical GroupDermatitis, Atopic; Inflammation; Nasal Polyps; Rhinitis, Allergic; Rhinitis, Allergic, Seasonal; Sinusitis
Details
SHR-1819SHR-1819Phase 3 ClinicalShanghai Hengrui Pharmaceutical Co LtdAsthma; Chronic Urticaria; Dermatitis, Atopic; Nasal Polyps; Prurigo; Prurigo Nodularis; Rhinitis, Allergic; Rhinitis, Allergic, Seasonal; Sinusitis
Details
JNJ-5939JNJ-5939; NM-26; NM26-2198; JNJ-95475939Phase 2 ClinicalNumab Therapeutics AgDermatitis, Atopic; Inflammation
Details
AK-139AK139; AK-139Phase 2 ClinicalKangfang Biotechnology (Cayman) Co LtdAsthma; Chronic rhinosinusitis with nasal polyps (CRSwNP); Chronic Urticaria; Dermatitis, Atopic; Hypersensitivity; Prurigo Nodularis; Pulmonary Disease, Chronic Obstructive; Rhinitis, Allergic; Rhinitis, Allergic, Seasonal
Details
IBI-3002IBI3002; IBI-3002Phase 2 ClinicalAsthma; Dermatitis, Atopic
Details
SHR-4597SHR-4597; SHR4597Phase 2 ClinicalGuangdong Hengrui Pharmaceutical Co LtdAsthma
Details
RC-1416RC14/16; RC-1416Phase 2 ClinicalNanjing RegeneCore Biotech Co LtdAsthma; Dermatitis, Atopic; Pulmonary Disease, Chronic Obstructive
Details
BA-2101BA-2101; BA2101; PR-103; PR103Phase 2 ClinicalShandong Boan Biotechnology Co LtdAsthma; Chronic Urticaria; Dermatitis, Atopic; Nasal Polyps; Prurigo; Pruritus; Pulmonary Disease, Chronic Obstructive; Sinusitis; Urticaria
Details
Sorafenib Tosylate/ComekibartMG-D-1609Phase 2 ClinicalMetagone Biotech IncSolid tumours
Details
LQ-036LQ-036Phase 2 ClinicalShanghai Novamab Biopharmaceuticals Co LtdAsthma; Pulmonary Disease, Chronic Obstructive
Details
Dupixent biosimilar (Chong Kun Dang Pharmaceutical)CKD-706Phase 1 ClinicalChong Kun Dang Pharmaceutical CorpDermatitis, Atopic
Details
Dupilumab biosimilar (China Resources Biopharma)Phase 1 ClinicalChina Resources Biopharmaceutical Co LtdDermatitis, Atopic
Details
Dupilumab biosimilar (Jiangsu Jingxing Pharma)Phase 1 ClinicalJiangsu Jingxing Pharmaceutical Technology Co LtdDermatitis, Atopic
Details
Dupilumab biosimilar (Chengdu Kanghong)KH-816; KH816Phase 1 ClinicalChengdu Kanghong Biotechnologies Co LtdDermatitis, Atopic
Details
BR-2060BR-2060; BR2060Phase 1 ClinicalZhejiang BioRay Biopharmaceuticals Co LtdAutoimmune Diseases; Dermatitis, Atopic
Details
Dupilumab biosimilar (Jushi Biopharma)Phase 1 ClinicalJushi Biopharmaceutical Co LtdDermatitis, Atopic
Details
BBT-001BBT001; BBT-001Phase 1 ClinicalBambusa Therapeutics IncDermatitis, Atopic
Details
Dupilumab biosimilar (Bio-Thera Solutions)BAT2406; BAT-2406Phase 1 ClinicalBio-Thera Solutions LtdAsthma; Dermatitis, Atopic; Eosinophilic Esophagitis; Nasal Polyps; Prurigo Nodularis; Sinusitis
Details
APG-808APG808; PR-001; PR001; APG-808Phase 1 ClinicalApogee Therapeutics Inc, Paragon Therapeutics IncPulmonary Disease, Chronic Obstructive
Details
HY-1770HY-1770; HT-17; HT17; YF02; HT25; GH02; HY1770Phase 1 ClinicalSuzhou Pharmavan Co LtdDermatitis, Atopic; Plaque psoriasis
Details

Inverkehr gebrachte Arzneimittelinformation

Englischer NameForschungscodeForschungsphaseFirmaFrühestes MarkennameFrühestes GenehmigungslandFrüheste IndikationFrüheste GenehmigungsgesellschaftFrüheste GenehmigungsdatumIndikationenKlinische Studie
StapokibartCM-310ApprovedKeymed Biosciences Co Ltd康悦达, KangyuedaMainland ChinaDermatitis, AtopicChengdu Kangnuoxing Biopharma Inc2024-09-10Asthma; Chronic rhinosinusitis with nasal polyps (CRSwNP); Conjunctivitis, Allergic; Dermatitis, Atopic; Nasal Polyps; Pemphigoid, Bullous; Prurigo; Prurigo Nodularis; Pruritus; Pulmonary Disease, Chronic Obstructive; Rhinitis, Allergic; Rhinitis, Allergic, Seasonal; Sinusitis; Solid tumours
Details
DupilumabREGN-668; SAR-231893ApprovedRegeneron Pharmaceuticals Inc, SanofiDupixent, 达必妥United StatesDermatitis, AtopicRegeneron Pharmaceuticals Inc2017-03-28Allergic Fungal Rhinosinusitis; Alopecia Areata; Angioedema; Aspergillosis, Allergic Bronchopulmonary; Asthma; Asthma, Aspirin-Induced; Chronic Urticaria; Colitis, Ulcerative; Conjunctivitis, Allergic; Coronavirus Disease 2019 (COVID-19); Dermatitis; Dermatitis, Atopic; Eczema; Eosinophilic Esophagitis; Eosinophilic gastroenteritis (EG); Genetic Diseases, Inborn; Hypereosinophilic Syndrome; Hypersensitivity; Hypersensitivity, Immediate; Keloid; Keratoconjunctivitis; Lichenoid Eruptions; Milk Hypersensitivity; Nasal Polyps; Nephrotic Syndrome; Neurodermatitis; Paranasal Sinus Diseases; Peanut Hypersensitivity; Pemphigoid, Bullous; Prostatic Neoplasms; Prurigo; Prurigo Nodularis; Pruritus; Pulmonary Disease, Chronic Obstructive; Respiration Disorders; Respiratory Sounds; Respiratory Tract Diseases; Rhinitis, Allergic; Scleroderma, Localized; Sinusitis; Skin Diseases; Skin Diseases, Eczematous; Sleep Apnea Syndromes; Urticaria
Details

Produktrezensionen

  • Molekülinformation
  • Produktliste
  • Inverkehr gebrachte Arzneimittelinformation
  • Produktrezensionen
  • Klinische Arzneimittelinformation
Kontaktieren Sie uns